Navigation Links
Cytochroma Announces Positive Comparative Data on CTA018 in Chronic Kidney Disease Model
Date:11/6/2008

quently by diabetes or hypertension, both of which are consequences of a growing obesity epidemic in countries worldwide.

About Secondary Hyperparathyroidism

SHPT is a condition commonly associated with CKD in which the parathyroid glands secrete excessive amounts of PTH. Excess PTH secretion arises as a result of impaired kidneys that are neither able to produce sufficient quantities of vitamin D hormones to suppress excessive PTH secretion nor maintain a state of balance (homeostasis) between calcium and phosphorus in the body. Prolonged elevation of PTH causes excessive calcium to be released from bone into the blood, leading to softening of the bones (osteomalacia) and calcification of vascular tissues. SHPT affects 40-60% of patients with moderate CKD and approximately 90% of patients with severe CKD.

About Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation (MTPC) is a research-driven global biopharmaceutical leader based in Japan, specializing in research, development and marketing of globally competitive pharmaceutical products focused on cardiovascular and metabolic disorders, and immune and inflammatory diseases. In particular, MTPC strategically focuses on drug discovery in the field of diabetes including a broad range of clinical states from metabolic risks (obesity/dyslipidemia) to complications (renal dysfunction/dialysis) and stroke, including the total range of disease phases such as acute phase, convalescence and maintenance. MTPC is currently developing two Phase III clinical candidates in the U.S. and EU: MP-146 for CKD and MCI-196 for hyperphosphatemia.

MTPC, established through the merger of Tanabe Seiyaku Co., Ltd. and Mitsubishi Pharma Corporation in October 2007, is committed to protecting the health of people around the world and contributing to comfortable lifestyles through creating pharmaceuticals.

For more information about MTPC, please visit

SOURCE Cytochroma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... NJ (PRWEB) July 29, 2014 ... free of blood and protein soils where it ... Miele, the world’s leading manufacturer of premium domestic ... to verifying surgical instruments are effectively cleaned. The ... of surgical instruments immediately after processing. After 3 ...
(Date:7/29/2014)... is in principle suitable to find out which preferences ... it in health economic evaluations, some (primarily methodological) issues ... of a pilot project by the German Institute for ... Analytic Hierarchy Process (AHP), CA is the second method ... Summarize outcome-specific results to an overall value ...
(Date:7/29/2014)... new lung is grown for a patient in need, using ... injection of replacement cells will enable a patient to self-heal ... ALERT: For audio and video of Dr. Keller and Jorge ... Mayo Clinic News Network . , Regenerative ... gift from Jorge and Leslie Bacardi of the Bahamas will ...
(Date:7/29/2014)... Foot Levelers Chairman and CEO Kent S. Greenawalt ... (FCA) National Convention and Expo, speaking on Ground Force ... on Thursday, August 20th at the Hyatt Regency in ... impact functional foot orthotics, like Foot Levelers Stabilizing Orthotics, ... fasciitis, and hammertoes. , Invented by a chiropractor in ...
(Date:7/29/2014)... July 29, 2014 1WorldSync announces ... leading healthcare suppliers will utilize the Global Data ... information network to share product information with the ... trading partners across their global supply chain. Holger ... at B. Braun: "B. Braun serves customers in ...
Breaking Medicine News(10 mins):Health News:ProCare Protein Check Tests Surgical Instruments to Verify Effective Cleaning 2Health News:Determine patient preferences by means of conjoint analysis 2Health News:Determine patient preferences by means of conjoint analysis 3Health News:Determine patient preferences by means of conjoint analysis 4Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 2Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 3Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 4Health News:Foot Levelers CEO Kent Greenawalt Speaking at FCA Convention 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3
... say the drug clodronate is an effective treatment for patients ... studied more than 1,000 patients // with breast cancer. Patients ... day or a placebo for five years. ,Results showed ... to their bones. Fifty-one of these patients were treated with ...
... identified a protein that essentially blocks HIV replication, in ... is not as effective at stopping HIV, say the ... of Nature. The team, headed by Joseph Sodroski, is ... Infectious Diseases (NIAID). ,"Identification of this HIV-blocking ...
... According to recent findings researchers say the risks and ... to be re-evaluated.// Researchers from Sweden studied more than ... of age. Participants had their intellectual capacity tested at ... school attendance records for the young men. ,Results ...
... pressure at home may lead to fewer blood pressure ... at patients’ homes to conventional doctors’ office measurements of ... patients with a diastolic blood pressure reading of 95 ... offices were included for the study. All of the ...
... a new treatment can now help chronic chest pain sufferers ... other antianginal medications it was found to improve the total ... ,Ranolazine is currently under review by the FDA. ... angina were randomly assigned to receive a placebo or one ...
... a non-surgical technique used to eliminate alternate pathways ... // Researchers now say that congestive heart failure ... of irregular heart rhythm experience significant improvement ... catheter ablation. ,58 patients with congestive heart ...
Cached Medicine News:
(Date:7/29/2014)... -- Encision Inc. (OTCQB:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of $2.476 ... or $(0.02) per share. These results compare to net ... $311 thousand, or $(0.04) per share, in the year-ago ...
(Date:7/28/2014)... , July 28, 2014 Pharmacyclics, Inc. (the "Company") ... hold a conference call and audio webcast to discuss financial ... Market closes on Thursday, July 31, 2014 at 4:30 p.m. ... Date: July 31, 2014 Time: 4:30 PM ... 303-7908 International: (678) 373-0875 A webcast replay will ...
(Date:7/28/2014)...  MiMedx Group, Inc. (NASDAQ: MDXG ), an integrated ... bioimplants processed from human amniotic membrane, announced today its results ... include: , Revenue exceeds upper end of ... million , Quarter-over-quarter revenue grew by ... 181% over Q2 2013 and 40% sequentially over Q1 2014 ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2MiMedx Announces Record Second Quarter Results 2MiMedx Announces Record Second Quarter Results 3MiMedx Announces Record Second Quarter Results 4MiMedx Announces Record Second Quarter Results 5MiMedx Announces Record Second Quarter Results 6MiMedx Announces Record Second Quarter Results 7MiMedx Announces Record Second Quarter Results 8MiMedx Announces Record Second Quarter Results 9MiMedx Announces Record Second Quarter Results 10MiMedx Announces Record Second Quarter Results 11MiMedx Announces Record Second Quarter Results 12MiMedx Announces Record Second Quarter Results 13MiMedx Announces Record Second Quarter Results 14MiMedx Announces Record Second Quarter Results 15MiMedx Announces Record Second Quarter Results 16MiMedx Announces Record Second Quarter Results 17MiMedx Announces Record Second Quarter Results 18
... Phase II Trial Initiated by Myriad For Azixa(TM), ... and OMX Nordic Exchange: EPCT) today reported on ... agent,licensed by the Company to Myriad Genetics, Inc. ... agreement. (Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO ) ...
... DNDN ) today announced publication of results ... active cellular immunotherapy, in the,August 20 issue of ... safety profile, immune response and clinical activity of ... failed standard,therapy. "In addition to demonstrating that ...
Cached Medicine Technology:EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound 2EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound 3EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound 4EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound 5Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 2Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 3Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 4
... the industry strives to control costs, Omega ... for patients and providers by manufacturing high ... compact footprint allows installation in a minimal ... quality for identification of the smallest vessels. ...
... efficiency by reducing errors and eliminating costly ... solution, you can spend less time on ... more time on your patient care. Cardiology ... solution. With over 50,000 installations and a ...
... Manager® is now known as Centricity® Physician ... Office - PM is designed to fit ... an easily adaptable solution as individual as ... of every specialty and size - have ...
... VitalWorks' practice management systems have brought cutting-edge ... bases in the world. Today, Intuition PM ... in a friendly, intuitive manner. Automate patient ... expedite in-office patient processing through wireless hand-held ...
Medicine Products: